Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details) $ in Millions |
1 Months Ended | 12 Months Ended |
|---|---|---|
|
May 31, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
product
|
|
| Commitments and Contingencies | ||
| Estimate of milestone payments | $ 12.1 | |
| Assumed number of products per contract | product | 1 | |
| BioInvent License Agreement | ||
| Commitments and Contingencies | ||
| Contingent consideration | $ 10.0 | $ 10.0 |
| X | ||||||||||
- Definition Amount of contingent consideration recognized as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees. Represent contingent payments not recorded on balance sheet. No definition available.
|
| X | ||||||||||
- Definition Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations. No definition available.
|
| X | ||||||||||
- Details
|